In animal models of CRC, CAR-T with lymphocytes engineered to secrete RLN2 demonstrated enhanced tumor infiltration and superior antitumor activity compared with conventional CAR-T cells [20]. This evidence concerns the gene RLN2 and colorectal carcinoma.